Argus Product Tab Screens - Katalyst HLS

ARGUS
PRODUCT SCREEN
1
01/29/17
Katalyst Healthcares & Life Sciences

Product Information:
Spontaneous/Literature:
 At least one Novartis drug should be entered as suspect
 Two or more Novartis drugs can be entered as co-
suspect
 Only one case will be created
 Concomitant Novartis drugs are coded with WHO drug
dictionary
2
01/29/17Katalyst Healthcares & Life Sciences

Concomitant Medication & Treatments
 All co-medications should be entered in the Products
screen and marked concomitant
 All drugs used to treat the adverse event should be
entered in the Products screen and marked treatment
 Use the WHO Drug Coding List to select product name -
using the encode button for both concomitant and
treatment medication
3

Coding Medication:
 Product Name and Generic Name fields are
automatically populated from data entered in the
book-in screen
 Indication will also be automatically populated as
derived from book-in coding if the drug is coded to an
indication
 Therefore, ensure information is correct prior to product
selection
4

Trade Name Lookup
 The most critical fields are:
• Product
• Ingredient
• Formulation
• Indication
5

Trade Name Lookup
 The most critical fields are:
• Product
• Ingredient
• Formulation
• Indication
6

Coding of Novartis Drugs:
 Under country delete the country name and type in
- World1 to look for the local trade name
- World to look for the international trade name
- NH (for Novartis Pharma Headquarters) to look for the generic name
- NCH (Novartis Consumer Health) to look for products ‘owned’ by Consumer
Health.
- NVO (Novartis Ophthalmics) or ‘o-‘ to look for Ophtha products.
- NGX (Novartis Generics) to look for products ‘owned’ by Novartis Generics.
7

Coding of Novartis Drugs
8

Co-meds and Treatment meds
Therapy Details:
 Enter for concomitant and treatment medications
 Do not enter procedures, surgery, and non-drug
therapy as treatment
9

Product Information:
Concentration Units:
 should be used to capture strength of suspect formulation, if
provided
 Do not use this field for products which have an indication
linked to the product selection ie. Neoral
Formulation:
 should be left unchanged
10

Dosage Information:
Suspect/Concomitant Medication:
 For all cases enter all dosage information up until the onset of
the event
Treatment Medication:
 For all cases enter all known dosage information relevant to
the treatment of the event
11

Dosage Information:
Multiple dosage regimens:
 Enter in chronological order
 Relevant dosage changes leading up to an event/episode
(recurrent events) and during an event/episode can be added
up until the final resolution of the event/episode
Dosage range:
 when citing a range, use the minus key, not a dash (dashes do
not print out on the MedWatch form)
12

Dosage Regimens:
Stop dates:
 should not be entered where the patient has died
while on drug therapy
Dose Description:
 should always be filled in, if appropriate, as it maps
to regulatory forms
13

Dosage Regimens:
Patient Route of Administration:
 select the appropriate value from the drop down list, which
reflects the patient’s route of administration i.e. oral or type o
several times.
Parent Route of Administration:
 used in Baby cases to enter mother information of route of
administration
14

Action Taken
 Specifically refers to the suspect product,
not the event as a whole
 Only one action item can be entered
 If more than one action, use most relevant term- the discontinued
option should have higher priority
15

Dechallenge:
 Tick the appropriate checkbox:
• Positive: drug was stopped and the event/symptoms
improved/disappeared
• Negative: drug was stopped and the event/symptoms
did not improve/go away or patient has
sequelae
• N/A: drug was not stopped
• Unknown: the result of the dechallenge is unknown
Definition: when the drug has been
interrupted because of the event...
16

Rechallenge:
 Tick the appropriate checkbox:
• Positive: drug was re-introduced and symptoms reappeared
• Negative: drug was re-introduced and symptoms did not
reappear
• N/A: drug was not re-introduced
• Unknown: The result of the rechallenge is unknown
Definition: …if drug is then re-introduced
17

Thank YouThank You
&&
QuestionsQuestions
18
Contact:
Katalyst Healthcare’s & Life Sciences
South Plainfield, NJ, USA 07080.
E-Mail: info@KatalystHLS.com

Argus Product Tab Screens - Katalyst HLS

Recomendados

Recomendados

Mais conteúdo relacionado

Mais procurados

Mais procurados (20)

Destaque

Destaque (19)

Semelhante a Argus Product Tab Screens - Katalyst HLS

Semelhante a Argus Product Tab Screens - Katalyst HLS (20)

Mais de Katalyst HLS

Mais de Katalyst HLS (20)

Último

Último (20)

Argus Product Tab Screens - Katalyst HLS

Notas do Editor